Sign in
Back
Chronic Oxaliplatin-Based Chemotherapy in a Primary Ampullary Adenocarcinoma Patient without Significant Peripheral Neuropathy: Case Report and Literature Review
Journal article   Open access  Peer reviewed

Chronic Oxaliplatin-Based Chemotherapy in a Primary Ampullary Adenocarcinoma Patient without Significant Peripheral Neuropathy: Case Report and Literature Review

Nedal Bukhari and Eric Winquist
Case reports in oncology, Vol.10(2), pp.577-581
05/2017
DOI: https://doi.org/10.1159/000477841
PMCID: PMC5567005
PMID: 28868015

Abstract

Life Sciences & Biomedicine Oncology Science & Technology
Peripheral neuropathy is the most common dose-limiting toxicity associated with oxaliplatin. We report on a 61-year-old female patient with advanced primary ampullary adenocarcinoma who received 35 cycles of FOLFIRINOX (5-fluorouracil, irinotecan, and oxaliplatin) chemotherapy. The patient has tolerated this treatment without developing significant peripheral neuropathy. (C) 2017 The Author(s) Published by S. Karger AG, Basel
url
https://doi.org/10.1159/000477841View
Published (Version of record) Open

Metrics

1 Record Views

Details